RICARDO-UK-LTD
30.3.2021 01:03:06 CEST | Business Wire | Press release
Cranfield Aerospace Solutions (CAeS) - the UK SME leading the Project Fresson consortium - announces it will exploit recent advances in hydrogen fuel cell technology to develop a commercially viable, retrofit powertrain solution for the nine-passenger Britten-Norman Islander aircraft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005667/en/
Following a rigorous assessment of hydrogen technology innovators, CAeS is delighted to welcome Ricardo UK Ltd and Innovatus Technologies Ltd to the Fresson consortium. Ricardo UK Ltd brings expertise in fuel cell system development and Innovatus Technologies Ltd brings their innovative Scottish Hydrogen Fuel Tank (SHyFT) technology.
Steve Dyke, Managing Director Ricardo Automotive and Industrial EMEA Division said: “We are proud to join the Cranfield Aerospace Solutions consortium to play our part in helping to reduce the carbon footprint for commercial air passengers. We are already working on hydrogen and fuel cell technology, providing clean efficient solutions which reduce carbon and noxious emissions across a wide range of sectors. Our work for the Fresson consortium will enable us to consolidate and grow our hydrogen fuel cell and propulsion capability, so that Ricardo can achieve its ambition of becoming a world-leader in hydrogen and fuel cell services and solutions and help accelerate net zero transportation.”
Innovatus Technologies Ltd leads the field in next generation ultralightweight hydrogen tank design exploiting patented cellular core composite techniques. This is critical to the successful integration and exploitation of hydrogen fuel cell power systems in applications across aerospace, automotive, industrial, and marine sectors.
Ruan Swart, Chief Executive Officer Innovatus Technologies Ltd said: ““We are proud in being selected to join the Cranfield Aerospace Solutions, ‘Project Fresson’, consortium. Our unique and innovative SHyFT solution is game-changing in bringing zero carbon fuel cell energy to commercial reality in the transport sector. Project Fresson showcases important Scottish innovation and next generation hydrogen tank manufacturing in the UK.”
Project Fresson will deliver an emissions-free (zero CO2 ), hydrogen-fuel-cell-powered flying demonstrator by September 2022. Having completed a comprehensive evaluation of technologies and configurations for sustainable aircraft propulsion, the Fresson team concluded that hydrogen fuel cell technology is the optimum solution to meet environmental, regulatory and operational requirements for this size of aircraft, enabling zero carbon emissions and reducing operating costs. This has presented the Fresson consortium, which includes Britten-Norman and Cranfield University, with an opportunity to deliver an enhanced technology programme that surpasses the original demonstrator concept.
Paul Hutton, Chief Executive Officer, Cranfield Aerospace Solutions said: “This is incredibly important for the Project Fresson Team but also for everyone else around the world interested in zero emissions flight. This project can deliver the world’s first truly “green” passenger carrying airline services. The whole team is proud of what Project Fresson has achieved so far and excited about what is to come. I am very thankful for the support of the ATI and our investors for making this ground-breaking work a reality.”
Jenny Kavanagh, Chief Strategy Officer, Cranfield Aerospace Solutions added: “Covid-19 has caused the biggest crisis in aviation’s history. It’s important that, as the sector builds back better, it does so with sustainability at its heart. Project Fresson is more than just a technology demonstrator; it has one focus above all others: real operational and commercial viability.”
Project Fresson is supported by the ATI Programme, a joint Government and industry investment to maintain and grow the UK’s competitive position in civil aerospace design and manufacture. The programme, delivered through a partnership between the Aerospace Technology Institute (ATI), Department for Business, Energy & Industrial Strategy (BEIS) and Innovate UK, addresses technology, capability and supply chain challenges.
As a result of these changes, there is now no longer a need for the Rolls-Royce element of the aircraft programme. It is therefore Rolls-Royce’s intention to withdraw from Project Fresson and the consortium is going through the necessary steps for this to happen. We thank Rolls-Royce for its contribution to Project Fresson and wish its team well. Rolls-Royce will continue to actively research the use of hydrogen in aviation and this decision in no way reflects its overall view of hydrogen as a potential technology.
Ends
Notes to editors
- To follow the progress of Project Fresson, visit the microsite: www.projectfresson.uk or follow on Twitter @projectfresson.
- Cranfield Aerospace Solutions (CAeS) is an aerospace market leader in rapid prototyping of new aerospace concepts, modifications to existing aerospace platforms and integration of cutting-edge technologies to meet the most challenging issues facing the industry today. CAeS is the wholly owned commercial arm of Cranfield University. Visit: www.cranfieldaerospace.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005667/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom